About the Bing Center for Waldenström's Macroglobulinemia
The Bing Center for Waldenström's Macroglobulinemia (WM) is the largest center in the world that is dedicated to the study and development of new, targeted treatments for WM and related Immunoglobulin M (IgM) disorders including IgM related neuropathy, and Bing Neel Syndrome. The Center is credited with the discovery of the MYD88 and CXCR4 mutations in WM, the approval of the first ever drug for WM (ibrutinib), and advancement of numerous new drugs for WM through clinical trials.
The Bing Center for Waldenström's Macroglobulinemia provides a comprehensive range of services for patients with Waldenström's macroglobulinemia, including:
• Evaluations and ongoing clinical care
• Consultations (Second Opinions)
• Genomic Testing for WM relevant mutations including MYD88, CXCR4 and TP53
• Pathology review of biopsy samples
• Development of a personalized treatment plan offering the latest therapies (chemotherapy, biological and immune therapies)
• Access to clinical trials offering novel treatments
• Participation in laboratory studies including studies focused on WM genomics and new drug discovery
• Stem cell transplantation
• Complementary therapies through the Leonard P. Zakim Center for Integrative Therapies and Healthy Living
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
